Compare Abeona Therapeutics Inc (ABEO) vs STMicroelectronics NV (STM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs STMicroelectronics NV — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while STMicroelectronics NV trades at $67.62 (market cap $59.25B). The key difference: STMicroelectronics NV is far larger — about 158.7× Abeona Therapeutics Inc's market cap, and STMicroelectronics NV pays a 0.54% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | STM | |
|---|---|---|
Market Cap | $373.32M | $59.25B |
Sector | Health | Financials |
52-Week High | $7.23 | $79.91 |
52-Week Low | $4.17 | $21.20 |
Enterprise Value | $228.22M | $57.46B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
STM trades at $67.28, down 1.57% today, with a neutral technical signal and mixed earnings history. The company shows strong cash flow from operations at $2.15B in 2025 and maintains a solid balance sheet with $6.18B cash. Recent news highlights growth in AI, automotive, and industrial segments, including new product launches like the VL53L9 LiDAR module. Analyst consensus is a Buy with a $72.33 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given STM's strategic positioning in high-growth semiconductor markets, but high valuation ratios (P/E 446.19) and recent earnings misses pose risks. Revenue decline from $17.3B in 2023 to $11.8B in 2025 requires monitoring, though cost control and innovation in edge AI and automotive chips offer long-term opportunities amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
